NO20141479L - Bindingsmidler som inhiberer myostatin - Google Patents

Bindingsmidler som inhiberer myostatin

Info

Publication number
NO20141479L
NO20141479L NO20141479A NO20141479A NO20141479L NO 20141479 L NO20141479 L NO 20141479L NO 20141479 A NO20141479 A NO 20141479A NO 20141479 A NO20141479 A NO 20141479A NO 20141479 L NO20141479 L NO 20141479L
Authority
NO
Norway
Prior art keywords
binding agents
inhibit myostatin
myostatin
inhibit
binding
Prior art date
Application number
NO20141479A
Other languages
English (en)
Inventor
Thomas Charles Boone
Hosung Min
Hq Han
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US43592302P priority Critical
Priority to PCT/US2003/040781 priority patent/WO2004058988A2/en
Publication of NO20141479L publication Critical patent/NO20141479L/no
Application filed by Amgen Inc filed Critical Amgen Inc

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
NO20141479A 2002-12-20 2014-12-05 Bindingsmidler som inhiberer myostatin NO20141479L (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US43592302P true 2002-12-20 2002-12-20
PCT/US2003/040781 WO2004058988A2 (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin

Publications (1)

Publication Number Publication Date
NO20141479L true NO20141479L (no) 2005-09-08

Family

ID=32682298

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20053545A NO335982B1 (no) 2002-12-20 2005-07-19 Bindingsmidler som inhiberer myostatin, fremgangsmåte for deres fremstilling, farmasøytisk preparat derav og anvendelse derav for fremstilling av et preparat, fremgangsmåte for å påvise eller diagnostisere en myostatinrelatert forstyrrelse samt fremgangsmåte for å måle myostatin i en prøve.
NO20141479A NO20141479L (no) 2002-12-20 2014-12-05 Bindingsmidler som inhiberer myostatin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20053545A NO335982B1 (no) 2002-12-20 2005-07-19 Bindingsmidler som inhiberer myostatin, fremgangsmåte for deres fremstilling, farmasøytisk preparat derav og anvendelse derav for fremstilling av et preparat, fremgangsmåte for å påvise eller diagnostisere en myostatinrelatert forstyrrelse samt fremgangsmåte for å måle myostatin i en prøve.

Country Status (28)

Country Link
US (7) US7511012B2 (no)
EP (2) EP1581649B1 (no)
JP (3) JP4959137B2 (no)
KR (9) KR20130036378A (no)
CN (2) CN102382172A (no)
AR (2) AR042545A1 (no)
AT (1) AT496938T (no)
AU (2) AU2003301195B2 (no)
BR (1) BR0317538A (no)
CA (2) CA2510893C (no)
CY (1) CY1111388T1 (no)
DE (1) DE60335915D1 (no)
DK (1) DK1581649T3 (no)
EA (1) EA009056B1 (no)
ES (1) ES2359562T3 (no)
HK (1) HK1084419A1 (no)
IL (3) IL169168D0 (no)
ME (1) MEP57508A (no)
MX (1) MXPA05006521A (no)
NO (2) NO335982B1 (no)
NZ (1) NZ541253A (no)
PL (1) PL383616A1 (no)
PT (1) PT1581649E (no)
RS (1) RS52815B (no)
SI (1) SI1581649T1 (no)
TW (1) TWI328456B (no)
WO (1) WO2004058988A2 (no)
ZA (1) ZA200505481B (no)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP4429728B2 (ja) * 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン(follistatin)ドメイン含有タンパク質
PL375045A1 (xx) 2002-02-21 2005-11-14 Wyeth GASP1: protein containing the follistatin domain
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
BR0314380A (pt) * 2002-09-16 2005-07-19 Wyeth Corp Ativação de metaloprotease de miostatina e métodos de modulação da atividade de miostatina
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
KR20130036378A (ko) 2002-12-20 2013-04-11 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
WO2004108157A2 (en) * 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
AT540980T (de) 2003-11-13 2012-01-15 Hanmi Holdings Co Ltd Proteinkomplex mit immunglobulinfragment und verfahren zu dessen herstellung
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
KR20060120229A (ko) 2003-12-31 2006-11-24 쉐링-프라우 리미티드 중화 에피토프계 성장 증진 백신
CA2567810A1 (en) * 2004-05-27 2005-12-08 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
US9045553B2 (en) 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
EP1773400A2 (en) * 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
EP1797127B1 (en) * 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
CA2594276A1 (en) 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
WO2006102574A2 (en) * 2005-03-23 2006-09-28 Wyeth Detection of gdf-8 modulating agents
BRPI0609439A2 (pt) * 2005-03-23 2010-04-06 Wyeth Corp detecção de uma resposta imunológica a agentes moduladores de gdf-8
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc FORMULATIONS OF SELF-DAMPING PROTEIN.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
KR101135220B1 (ko) * 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
CA2624935C (en) 2005-10-12 2011-11-29 Eli Lilly And Company Anti-myostatin antibodies
US20090163579A1 (en) * 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
AU2006321906C1 (en) * 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EA015916B1 (ru) 2006-09-05 2011-12-30 Эли Лилли Энд Компани Моноклональные антитела к миостатину и их применения
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
JP2010512326A (ja) * 2006-12-08 2010-04-22 アクセルロン ファーマ, インコーポレイテッド Cerberus、Cocoおよびこれらの誘導体の使用
BR112014015003A2 (pt) 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
WO2008153745A2 (en) 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2009015345A1 (en) * 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
MX2009012558A (es) 2007-08-03 2010-04-21 Biomarin Iga Ltd COMBINATIONS OF PHARMACOS FOR THE TREATMENT OF MUSCULAR DISTROPHY OF DUCHENNE.
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
MX2010002249A (es) * 2007-08-31 2010-03-17 Amgen Inc FORMULATION OF SOLID STATE PROTEIN.
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
WO2009137880A1 (en) 2008-05-14 2009-11-19 Agriculture Victoria Services Pty Ltd Use of angiogenin or angiogenin agonists for treating diseases and disorders
LT2370463T (lt) 2008-11-26 2016-12-12 Amgen Inc. Stabilizuotas aktivino iib receptoriaus variantas
MX2011013898A (es) * 2009-06-22 2012-05-22 Amgen Inc REPLACED PROTEINS THAT USE A CHEMICALLY CONTROLLED OXIDE-REDUCTION STATE.
CA2765154A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
US8945511B2 (en) * 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AU2011265005B2 (en) 2010-06-07 2015-04-09 Amgen Inc. Drug delivery device
CN103221426B (zh) 2010-08-16 2016-01-13 安姆根公司 结合肌肉生长抑制素的抗体、组合物和方法
EP2691065B1 (en) 2011-03-31 2017-03-01 Amgen Inc. Vial adapter and system
MX364177B (es) 2011-04-20 2019-04-15 Amgen Inc Aparato autoinyector.
US9758548B2 (en) * 2011-05-11 2017-09-12 Technion Research & Development Foundation Limited Anti-microbial peptides and uses of same
EP3045188B1 (en) 2011-10-14 2020-12-23 Amgen Inc. Injector and method of assembly
EP2771038B1 (en) 2011-10-26 2018-10-10 Amgen Inc. Methods of reducing or eliminating protein modification and degradation arising from exposure to uv light
FR2982860B1 (fr) * 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies USE OF FIBROMODULIN AND LUMICAN TO INCREASE MUSCLE MASS
AU2013240271A1 (en) 2012-03-26 2014-10-02 Axcella Health Inc. Nutritive fragments, proteins and methods
US9605040B2 (en) 2012-03-26 2017-03-28 Axcella Health Inc. Nutritive proteins and methods
BR112014023792A2 (pt) 2012-03-26 2017-07-18 Pronutria Inc proteínas nutritivas carregadas e métodos
BR112014023869A2 (pt) 2012-03-26 2017-07-18 Pronutria Inc proteínas nutritivas carregadas e métodos
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
EP2880053B8 (en) 2012-08-01 2020-04-15 Ikaika Therapeutics, LLC Mitigating tissue damage and fibrosis via anti-ltbp4 antibody
EP3081249B1 (en) 2012-11-21 2020-12-30 Amgen Inc. Drug delivery device
JP6143270B2 (ja) * 2013-01-31 2017-06-07 学校法人東京薬科大学 マイオスタチン阻害ペプチド
TWI639453B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
CA2904725A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
AU2014238267B2 (en) 2013-03-22 2019-08-15 Amgen Inc. Injector and method of assembly
KR101523065B1 (ko) * 2013-06-19 2015-05-27 한국기초과학지원연구원 입자크기가 제어된 금 나노입자의 제조방법 및 제조된 금 나노입자를 이용한 비색식 강산 검출방법
WO2015035405A1 (en) * 2013-09-09 2015-03-12 Pinta Biotherapeutics, Inc. Myostatin antagonist for treatment of pew in esrd patients
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3060275B1 (en) 2013-10-24 2019-07-03 Amgen Inc. Injector and method of assembly
US20180193623A1 (en) 2014-02-05 2018-07-12 Amgen Inc. Drug delivery system with electromagnetic field generator
WO2015171777A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
AU2015271769A1 (en) 2014-06-03 2016-11-10 Amgen Inc. Systems and methods for remotely processing data collected by a drug delivery device
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
US20170368260A1 (en) 2014-12-19 2017-12-28 Amgen Inc. Drug delivery device with live button or user interface field
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US20180112232A1 (en) * 2015-04-23 2018-04-26 Washington State University Smad7 gene delivery as a therapeutic
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
US20190050375A1 (en) 2016-03-15 2019-02-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
RU2613420C1 (ru) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата
CN109414481A (zh) * 2016-04-25 2019-03-01 葛兰素史克知识产权开发有限公司 用于治疗病理性肌肉损失和虚弱的nope
US20190192766A1 (en) 2016-04-29 2019-06-27 Amgen Inc. Drug Delivery Device with Messaging Label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
EP3455142A1 (en) 2016-05-13 2019-03-20 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US10150115B2 (en) * 2016-07-21 2018-12-11 Spacepharma SA System and method for rehydrating powder and delivering the rehydrated powder to a reactor
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc INJECTION DEVICES AND RELATED METHODS OF USE AND ASSEMBLY.
JP2020508117A (ja) 2017-02-17 2020-03-19 アムジエン・インコーポレーテツド 薬物送達装置用の挿入機構
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
EP3592403A1 (en) 2017-03-06 2020-01-15 Amgen Inc. Drug delivery device with activation prevention feature
US20200238004A1 (en) 2017-03-07 2020-07-30 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
EP3592404A1 (en) 2017-03-09 2020-01-15 Amgen Inc. Insertion mechanism for drug delivery device
MX2019011416A (es) 2017-03-28 2019-11-01 Amgen Inc SYSTEM AND METHOD FOR ASSEMBLY OF SYRINGE AND PLUNGER STEM.
CA3061982A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
EP3634546A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Torque driven drug delivery device
US20200206429A1 (en) 2017-06-22 2020-07-02 Amgen Inc Device activation impact/shock reduction
EP3641861A1 (en) 2017-06-23 2020-04-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
US20200230313A1 (en) 2017-07-14 2020-07-23 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
JP2020528292A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US20190060562A1 (en) 2017-08-22 2019-02-28 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717A1 (en) 2017-10-04 2020-08-12 Amgen Inc. Flow adapter for drug delivery device
EP3691716A1 (en) 2017-10-06 2020-08-12 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703779A1 (en) 2017-11-03 2020-09-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
SG11202002966QA (en) 2017-11-10 2020-05-28 Amgen Inc Plungers for drug delivery devices
CA3079540A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
AU2018368338A1 (en) 2017-11-16 2020-04-09 Amgen Inc. Autoinjector with stall and end point detection
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US20190365987A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Modular fluid path assemblies for drug delivery devices
KR20200008332A (ko) 2018-07-16 2020-01-28 강릉원주대학교산학협력단 구멍쇠미역 추출물을 포함하는 근력강화 또는 근감소증의 예방 및 치료용 조성물
KR102042352B1 (ko) 2018-07-16 2019-11-07 강릉원주대학교산학협력단 땅콩 껍질 추출물을 포함하는 근력강화 또는 근감소증의 예방 및 치료용 조성물
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
CN112469454A (zh) 2018-07-24 2021-03-09 安进公司 用于施用药物的输送装置
CN112351804A (zh) 2018-07-24 2021-02-09 安进公司 用于施用药物的输送装置
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
WO2020072846A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
US20200114082A1 (en) 2018-10-15 2020-04-16 Amgen Inc. Drug delivery device having damping mechanism
TW202031306A (zh) 2018-10-15 2020-09-01 美商安進公司 用於藥物遞送裝置之平台組裝方法
TW202033949A (zh) 2018-10-23 2020-09-16 美商安進公司 用於即時預測的拉曼光譜模型之自動校準及自動維護
WO2020091981A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TW202100191A (zh) 2018-11-01 2021-01-01 美商安進公司 部分針頭縮回之藥物遞送裝置
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
WO2020219482A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
EP0618804A4 (en) 1991-10-08 1995-06-07 Univ Duke PEPTIDE CORRESPONDING TO ANTIGENIC DETERMINANTS OF THE ACQUIRED IMMUNODEFICITARY SYNDROME HTLV.
DE69432815T2 (de) 1993-03-19 2003-12-11 Univ Johns Hopkins Med Wachstumsfaktor-8
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
EP1027608B1 (en) * 1998-07-30 2010-01-20 Odyssey Thera, Inc. Protein fragment complementation assays
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP1002068B1 (en) * 1997-07-14 2009-09-09 University of Liège Mutations in the myostatin gene cause double-muscling in mammals
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
JP4544742B2 (ja) * 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Gdf−8の阻害による糖尿病の処置法
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE60027135T2 (de) * 1999-01-21 2007-01-11 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
EA005248B1 (ru) * 1999-07-20 2004-12-30 Фармекса А/С Способ отрицательной регуляции активности gdf-8
AU782925B2 (en) 2000-01-18 2005-09-08 Orico Limited Myostatin and mimetics thereof
CA2402780A1 (en) * 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
CA2432474C (en) * 2000-12-23 2012-06-26 Dyax Corp. Fibrin binding polypeptides useful inter alia in medical imaging processes
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
KR20130036378A (ko) 2002-12-20 2013-04-11 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
EP1677816B1 (en) 2003-10-06 2014-03-12 Paranta Biosciences Limited Follistatin for use in down-regulation an inflammatory response
AT540980T (de) 2003-11-13 2012-01-15 Hanmi Holdings Co Ltd Proteinkomplex mit immunglobulinfragment und verfahren zu dessen herstellung
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005084699A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
EA014112B1 (ru) 2004-03-23 2010-10-29 Эли Лилли Энд Компани Моноклональное антитело к миостатину и способы его применения
EP1797127B1 (en) * 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
DK1915397T3 (en) 2005-08-19 2015-04-20 Wyeth Llc Antagonist AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8-ASSOCIATED DISEASES
CA2624935C (en) 2005-10-12 2011-11-29 Eli Lilly And Company Anti-myostatin antibodies
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1

Also Published As

Publication number Publication date
ES2359562T3 (es) 2011-05-24
JP4959137B2 (ja) 2012-06-20
KR20130036378A (ko) 2013-04-11
EA200501000A2 (ru) 2006-06-30
DE60335915D1 (de) 2011-03-10
AT496938T (de) 2011-02-15
CN101287484B (zh) 2012-10-10
NO20053545L (no) 2005-09-08
JP2010193888A (ja) 2010-09-09
SI1581649T1 (sl) 2011-09-30
EP1581649A4 (en) 2008-10-08
ZA200505481B (en) 2008-01-30
TW200505474A (en) 2005-02-16
US7928075B2 (en) 2011-04-19
KR20150013350A (ko) 2015-02-04
PL383616A1 (xx) 2008-04-14
AU2010201389A1 (en) 2010-04-29
NZ541253A (en) 2010-03-26
EP2272864A3 (en) 2011-02-16
DK1581649T3 (da) 2011-05-02
HK1084419A1 (en) 2006-07-28
KR20110086881A (ko) 2011-08-01
KR20150107899A (ko) 2015-09-23
BR0317538A (pt) 2005-11-29
KR20050091015A (ko) 2005-09-14
RS20050530A (en) 2007-09-21
KR20140004805A (ko) 2014-01-13
IL169168D0 (en) 2007-07-04
KR20120037517A (ko) 2012-04-19
US8071538B2 (en) 2011-12-06
US20130230515A1 (en) 2013-09-05
CA2510893C (en) 2012-07-10
NO335982B1 (no) 2015-04-13
PT1581649E (pt) 2011-04-13
IL205265D0 (en) 2011-07-31
US7511012B2 (en) 2009-03-31
US20120083442A1 (en) 2012-04-05
JP2013048622A (ja) 2013-03-14
JP2006524034A (ja) 2006-10-26
RS52815B (en) 2013-10-31
CN102382172A (zh) 2012-03-21
CY1111388T1 (xx) 2015-08-05
EA009056B1 (ru) 2007-10-26
WO2004058988A2 (en) 2004-07-15
CA2774928A1 (en) 2004-07-15
KR20120060250A (ko) 2012-06-11
US20100330072A1 (en) 2010-12-30
AU2003301195B2 (en) 2010-01-07
MEP57508A (xx) 2011-05-10
KR101304718B1 (ko) 2013-09-05
IL205266D0 (en) 2011-07-31
CA2510893A1 (en) 2004-07-15
AU2003301195A1 (en) 2004-07-22
US20040181033A1 (en) 2004-09-16
TWI328456B (en) 2010-08-11
EP1581649B1 (en) 2011-01-26
KR20160045936A (ko) 2016-04-27
AR097588A2 (es) 2016-03-23
EA200501000A3 (ru) 2007-04-27
MXPA05006521A (es) 2005-08-26
US20090227517A1 (en) 2009-09-10
US20150175687A1 (en) 2015-06-25
WO2004058988A3 (en) 2007-11-15
US8920798B2 (en) 2014-12-30
EP2272864A2 (en) 2011-01-12
AR042545A1 (es) 2005-06-22
IL205265A (en) 2017-01-31
EP1581649A2 (en) 2005-10-05
US20090220491A1 (en) 2009-09-03
CN101287484A (zh) 2008-10-15
NO20053545D0 (no) 2005-07-19
US7803923B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
NO2017053I2 (no) Rolapitant
NO20150303L (no) Proteasominhibitorer
NO2014008I2 (no) Linagliptin
NO2018012I2 (no) Padeliporfin
NO337775B1 (no) Overtrekk
NO20054076D0 (no) Boresko.
NO20032883L (no) Bolgekraftverk.
NO20035476D0 (no) Azaindoler
NO20041983L (no) C-5-modifiserte indazolylprrolotriaziner
NO20015159D0 (no) Trille
NO20033593L (no) Kinazoliner som MMP-13 inhibitorer
NO20040686L (no) Forbindelser som pavirker glukokinase
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20033572D0 (no) Viskoelastiske blandinger
NO20050973L (no) Polyaldiminer
NO20043780L (no) Dreietang
ITMI20041123A1 (it) Fissaggio
NO20052733D0 (no) C-6 modifiserte indazolylpyrrolotriaziner
ITMI20030310V0 (it) Cerniera
NO20051688D0 (no) Farmasoytiske blandinger som har en modifisert baerer
NO20053663D0 (no) Transdermal granistetron
NO20024454L (no) Pappall
NO20030730D0 (no) Synergistisk biocidsammensetning
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
NO20031423L (no) Traktepose